Jul, 2018

Global
News / Media
-Enrollment of EV-201 Pivotal Trial Cohort Designed to Support Potential Expedited Registration Pathway in the U.S. Completed- -First Patient Dosed in Phase 3 Global Confirmatory Trial- BOTHELL, Wash., and TOKYO, July 9, 2018 – Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced completion of enrollment f...
Read More
Global
News / Media
TOKYO, July 2, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that it has received an approval for the marketing application of Dafclir® Tablets (generic name: fidaxomicin) for the treatment of infectious enteritis (including pseudomembranous colitis1) (susceptible strains: fidaxomicin susceptible Clostridium difficile (CD)2) in Japan...
Read More

Jun, 2018

Global
News / Media
Results show enzalutamide plus androgen deprivation therapy significantly reduced the risk of developing metastases or death by 71 percent compared to placebo plus androgen deprivation therapy TOKYO, June 29, 2018 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that results from the pivotal Phase 3 PROSPER trial, which evaluated enzalutamid...
Read More
Global
News / Media
Tokyo, June 28, 2018 - Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that it has been selected for the seventh consecutive year to be included in the FTSE4Good Index Series, one of the world’s premier indices for socially responsible investment. Out of 14 themes, Astellas received high marks for “Climate Change”, “Labor Standards” and “Corporate Govern...
Read More
Nothing Found

Unfortunately, we weren't able to find a match for your search query. Please try again.

Nothing Found

Unfortunately, we weren't able to find a match for your search query. Please try again.

Nothing Found

Unfortunately, we weren't able to find a match for your search query. Please try again.